Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
D000179:Acrylates / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D003327:Coronary Disease / Q000453:epidemiology* / Q000517:prevention & control; D005060:Europe; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D020521:Stroke / Q000453:epidemiology* / Q000517:prevention & control; D015996:Survival Rate; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D000179:Acrylates; D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan